Purpose. Based on the assumption that bronchial asthma has certain neurogenic paroxysmal mechanism and links with other paroxysmal diseases - breath-holding attacks, epilepsy and migraine, we decided to search antiasthmatic activity of carbamazepine, and the frequency of EEG and neurological signs during asthma. We also investigated correlates of these signs with asthma signs.
Methods. The efficacy of carbamazepine in these patients in randomized, double-blind, placebo-controlled trial was investigated. The EEG (brain-mapping) also was performed in these patients.
Results. EEG signs were found in 43 patients (72.9%). No increased convulsive predisposition was found. Some correlates of asthma signs with neurological and EEG signs were found. Complete and stable remission was achieved in 33 patients (73%) of carbamazepine group (n=45) during 3-month treatment, when all other antiasthmatic therapy was stopped. Asthma attacks completely disappeared, peak-flow rates increased till normal levels. No significant improvement were founded in patients of placebo group (n=14). Follow-up study confirmed high and stable efficacy of carbamazepine and some other anticonvulsants during asthma.
Conclusions. Based on high efficacy of monotherapy by anticonvulsants and high incidence of EEG signs in asthmatic patients, we consider bronchial asthma as neurogenic paroxysmal and inflammatory disease with complex pathogenic mechanisms, when allergic reactions are only trigger factors, and initial paroxysmal and inflammatory generator mechanisms of asthma lay in central nervous system.